查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1763997

腫瘤學人工智慧市場－全球產業規模、佔有率、趨勢、機會和預測，按成分、癌症類型、治療類型、地區和競爭細分，2020-2030 年

AI in Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component, By Cancer Type, By Treatment Type, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 172 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球腫瘤人工智慧市場價值為 7.0108 億美元，預計到 2030 年將以 9.43% 的複合年成長率成長。由於全球癌症負擔加重以及對更準確、更有效的診斷和治療方案的需求不斷成長，市場正獲得強勁發展勢頭。人工智慧透過實現早期檢測、影像分析、病理解釋和個人化治療計劃，在腫瘤學中發揮變革性的作用。機器學習演算法、深度學習以及與 MRI 和 CT 掃描等成像技術的整合等創新正在提高診斷的精確度。監管機構的批准，例如 FDA 批准的人工智慧癌症檢測設備，以及支援精準腫瘤學的 Tempus+ 等平台，正在加速其應用。此外，醫療機構、學術機構和人工智慧公司之間的合作也促進了技術進步。人工智慧能夠分析大量資料集並支援即時臨床決策，這使它成為從診斷到治療後監測的癌症治療的重要工具。

市場概覽
預測期 2026-2030
2024年市場規模 7.0108億美元
2030年市場規模 12.0102億美元
2025-2030 年複合年成長率 9.43%
成長最快的領域 化療
最大的市場 北美洲

關鍵市場促進因素

提高診斷準確性

主要市場挑戰

互通性和資料整合

主要市場趨勢

人工智慧驅動的放射組學

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球腫瘤學人工智慧市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按組件（軟體解決方案、硬體、服務）
    • 依癌症類型（乳癌、肺癌、攝護腺癌、大腸癌、腦瘤、其他）
    • 依治療類型（化療、放療、免疫療法、其他）
    • 按地區（北美、歐洲、亞太、南美、中東和非洲）
    • 按公司分類（2024）
  • 市場地圖

第6章：北美腫瘤人工智慧市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲腫瘤人工智慧市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區腫瘤人工智慧市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美洲腫瘤學人工智慧市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲腫瘤人工智慧市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球腫瘤學人工智慧市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Azra AI.
  • IBM Corp.
  • Siemens Healthcare GmbH.
  • Intel Corporation.
  • GE HealthCare.
  • NVIDIA Corporation.
  • Digital Diagnostics Inc.
  • ConcertAI.
  • Median Technologies.
  • PathAI.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 16179

The Global AI in Oncology Market was valued at USD 701.08 Million in 2024 and is projected to grow at a CAGR of 9.43% through 2030. The market is gaining strong momentum due to the increasing global burden of cancer and the growing demand for more accurate and efficient diagnostic and treatment options. Artificial intelligence is playing a transformative role in oncology by enabling early detection, image analysis, pathology interpretation, and personalized treatment planning. Innovations such as machine learning algorithms, deep learning, and integration with imaging technologies like MRI and CT scans are enhancing diagnostic precision. Regulatory approvals, such as the FDA's clearance of AI-powered cancer detection devices, and platforms like Tempus+ that support precision oncology, are accelerating adoption. Additionally, collaborations between healthcare providers, academic institutions, and AI companies are contributing to technological advancements. AI's ability to analyze vast datasets and support real-time clinical decisions is positioning it as a vital tool in cancer care, from diagnosis to post-treatment monitoring.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 701.08 Million
Market Size 2030USD 1,201.02 Million
CAGR 2025-20309.43%
Fastest Growing SegmentChemotherapy
Largest MarketNorth America

Key Market Drivers

Improving Diagnostic Accuracy

AI's ability to interpret medical images with high precision is driving its adoption in oncology. By identifying complex patterns in radiological scans such as MRIs and CTs, AI supports early cancer detection and improves diagnostic outcomes. A 2022 NCBI study emphasized how AI significantly enhances the detection of mammographic abnormalities, helping healthcare professionals diagnose cancer at earlier, more treatable stages. Unlike human interpretation, which can vary due to fatigue or experience, AI delivers consistent, objective analysis. This reduces the risk of misdiagnosis and increases confidence among clinicians. Moreover, AI-driven systems support cancer screening programs by efficiently analyzing high volumes of imaging and pathology data, improving throughput and reducing diagnostic delays across healthcare systems.

Key Market Challenges

Interoperability and Data Integration

Data fragmentation across healthcare systems is a major barrier to the seamless deployment of AI in oncology. Variations in electronic health record (EHR) platforms, imaging technologies, and data formats hinder the ability to integrate and standardize patient data. For AI systems to function effectively, comprehensive access to medical history, imaging records, and genomic profiles is critical. However, lack of compatibility and uniform standards often leads to inconsistent or incomplete data inputs. This affects the reliability of AI-driven recommendations and creates trust issues among healthcare providers. Data integration challenges also slow the training and validation of AI models, ultimately impacting clinical adoption and scalability.

Key Market Trends

AI-Driven Radiomics

AI-powered radiomics is emerging as a key trend, enabling the extraction of detailed imaging features that reflect tumor behavior and biological properties. By analyzing micro-patterns and textures in medical scans, AI systems can detect cancer early, even before clinical symptoms arise. Radiomics not only improves diagnosis but also plays a pivotal role in treatment personalization. AI can link image-based features with molecular and genetic data, guiding precision therapies. Additionally, radiomics tools assist in real-time treatment monitoring by tracking how tumors respond to specific interventions. These systems enhance decision-making and reduce variability in radiological assessments. As AI radiomics becomes more integrated into oncology workflows, it is redefining standards for cancer screening, diagnosis, and outcome prediction.

Key Market Players

  • Azra AI
  • IBM
  • Siemens Healthcare GmbH
  • Intel Corporation
  • GE HealthCare
  • NVIDIA Corporation
  • Digital Diagnostics Inc.
  • ConcertAI
  • Median Technologies
  • PathAI

Report Scope:

In this report, the Global AI in Oncology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

AI in Oncology Market, By Component:

  • Software Solutions
  • Hardware
  • Services

AI in Oncology Market, By Cancer Type:

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Brain Tumor
  • Others

AI in Oncology Market, By Treatment Type:

  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Others

AI in Oncology Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global AI in Oncology Market.

Available Customizations:

Global AI in Oncology market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global AI in Oncology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Component (Software Solutions, Hardware, Services)
    • 5.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
    • 5.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
    • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America AI in Oncology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component (Software Solutions, Hardware, Services)
    • 6.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
    • 6.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States AI In Oncology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Component
        • 6.3.1.2.2. By Cancer Type
        • 6.3.1.2.3. By Treatment Type
    • 6.3.2. Canada AI In Oncology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Component
        • 6.3.2.2.2. By Cancer Type
        • 6.3.2.2.3. By Treatment Type
    • 6.3.3. Mexico AI In Oncology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Component
        • 6.3.3.2.2. By Cancer Type
        • 6.3.3.2.3. By Treatment Type

7. Europe AI In Oncology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component (Software Solutions, Hardware, Services)
    • 7.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
    • 7.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France AI In Oncology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Cancer Type
        • 7.3.1.2.3. By Treatment Type
    • 7.3.2. Germany AI In Oncology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Cancer Type
        • 7.3.2.2.3. By Treatment Type
    • 7.3.3. United Kingdom AI In Oncology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Cancer Type
        • 7.3.3.2.3. By Treatment Type
    • 7.3.4. Italy AI In Oncology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Component
        • 7.3.4.2.2. By Cancer Type
        • 7.3.4.2.3. By Treatment Type
    • 7.3.5. Spain AI In Oncology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Component
        • 7.3.5.2.2. By Cancer Type
        • 7.3.5.2.3. By Treatment Type

8. Asia-Pacific AI In Oncology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component (Software Solutions, Hardware, Services)
    • 8.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
    • 8.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China AI In Oncology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Cancer Type
        • 8.3.1.2.3. By Treatment Type
    • 8.3.2. India AI In Oncology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Cancer Type
        • 8.3.2.2.3. By Treatment Type
    • 8.3.3. Japan AI In Oncology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Cancer Type
        • 8.3.3.2.3. By Treatment Type
    • 8.3.4. South Korea AI In Oncology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Cancer Type
        • 8.3.4.2.3. By Treatment Type
    • 8.3.5. Australia AI In Oncology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Cancer Type
        • 8.3.5.2.3. By Treatment Type

9. South America AI In Oncology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component (Software Solutions, Hardware, Services)
    • 9.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
    • 9.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil AI In Oncology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Cancer Type
        • 9.3.1.2.3. By Treatment Type
    • 9.3.2. Argentina AI In Oncology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Cancer Type
        • 9.3.2.2.3. By Treatment Type
    • 9.3.3. Colombia AI In Oncology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Cancer Type
        • 9.3.3.2.3. By Treatment Type

10. Middle East and Africa AI In Oncology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component (Software Solutions, Hardware, Services)
    • 10.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
    • 10.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa AI In Oncology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Cancer Type
        • 10.3.1.2.3. By Treatment Type
    • 10.3.2. Saudi Arabia AI In Oncology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Cancer Type
        • 10.3.2.2.3. By Treatment Type
    • 10.3.3. UAE AI In Oncology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Cancer Type
        • 10.3.3.2.3. By Treatment Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global AI In Oncology Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Azra AI.
    • 15.1.1. Business Overview
    • 15.1.2. Product Offerings
    • 15.1.3. Recent Developments
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Key Personnel
    • 15.1.6. SWOT Analysis
  • 15.2. IBM Corp.
  • 15.3. Siemens Healthcare GmbH.
  • 15.4. Intel Corporation.
  • 15.5. GE HealthCare.
  • 15.6. NVIDIA Corporation.
  • 15.7. Digital Diagnostics Inc.
  • 15.8. ConcertAI.
  • 15.9. Median Technologies.
  • 15.10. PathAI.

16. Strategic Recommendations

17. About Us & Disclaimer